指南与共识心力衰竭与心肌病

射血分数保留型心衰失代偿患者心肌肌钙蛋白升高的相关因素及预后意义:美国心脏协会Get With The Guidelines-Heart Failure项目发现

Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program.
指南 / 共识 · JAMA Cardiol · 2017-01-01

基于Get With The Guidelines-Heart Failure登记,纳入2009年1月至2014年12月因失代偿性射血分数保留型心衰(EF≥50%)住院且有肌钙蛋白检测结果的34233例患者(224个中心,33.4%为男性,中位年龄79岁),22.6%存在肌钙蛋白升高。校正分析显示肌钙蛋白升高与院内死亡、住院时间延长、出院不能回家及30天死亡、30天再入院、1年死亡风险升高相关。

要点

  • 失代偿性HFpEF住院患者中22.6%(7732/34233)存在肌钙蛋白升高。
  • 肌钙蛋白升高与院内死亡风险升高相关(OR 2.19;95%CI 1.88-2.56)。
  • 肌钙蛋白I升高与30天死亡(HR 1.59)、30天再入院(HR 1.12)、1年死亡(HR 1.35)风险升高相关。

核心结论

  • 在急性失代偿性HFpEF患者中,肌钙蛋白升高与其他预测变量无关地与更差的院内及出院后结局相关。
  • 未来研究需要确定在失代偿性HFpEF患者中检测肌钙蛋白水平是否有助于风险分层。

研究设计与样本

  • Get With The Guidelines-HF登记的观察性分析,纳入2009年1月至2014年12月因失代偿性HFpEF(射血分数≥50%)住院且有肌钙蛋白T或肌钙蛋白I定量或分类检测结果的患者。
  • 共纳入224个中心的34233例HFpEF患者,33.4%为男性,中位年龄79岁;78.6%(n=26896)检测肌钙蛋白I,21.4%(n=7319)检测肌钙蛋白T。

主要发现

  • 22.6%(n=7732)患者存在肌钙蛋白升高。
  • 校正分析中,较高的血清肌酐水平、黑人种族、较大年龄和缺血性心脏病与肌钙蛋白升高相关。
  • 肌钙蛋白升高与院内死亡风险升高相关(OR 2.19;95%CI 1.88-2.56),与住院时间>4天相关(OR 1.38;95%CI 1.29-1.47),与出院回家可能性降低相关(OR 0.65;95%CI 0.61-0.71)。
  • 肌钙蛋白I升高与30天死亡风险升高相关(HR 1.59;95%CI 1.42-1.80),与30天全因再入院风险升高相关(HR 1.12;95%CI 1.01-1.25),与1年死亡风险升高相关(HR 1.35;95%CI 1.26-1.45)。

关键数值与推荐

  • 肌钙蛋白升高定义为依据各机构参考实验室的分类(升高 vs 正常)。
  • 肌钙蛋白升高组院内死亡OR 2.19(95%CI 1.88-2.56),住院时间>4天OR 1.38(95%CI 1.29-1.47),出院回家OR 0.65(95%CI 0.61-0.71)。
  • 肌钙蛋白I升高组30天死亡HR 1.59(95%CI 1.42-1.80),30天全因再入院HR 1.12(95%CI 1.01-1.25),1年死亡HR 1.35(95%CI 1.26-1.45)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Elevated levels of cardiac troponins are associated with adverse clinical outcomes among patients with heart failure (HF) and reduced ejection fraction. However, the clinical significance of troponin elevation in the setting of decompensated HF with preserved ejection fraction (HFpEF) is not well established. OBJECTIVE: To determine the clinical predictors of troponin elevation and its association with in-hospital and long-term outcomes among patients with decompensated HFpEF. DESIGN, SETTING, AND PARTICIPANTS: Observational analysis of Get With The Guidelines-HF registry participants who were admitted for decompensated HFpEF (ejection fraction ≥50%) from January 2009 through December 2014 and who had quantitative or categorical (elevated vs normal based on institution's reference laboratory) measures of troponin level (troponin T or troponin I, as available). MAIN OUTCOMES AND MEASURES: In-hospital outcomes (mortality, length of stay, and discharge destination) and postdischarge outcomes (30-day mortality, 30-day readmission rate, 1-year mortality). RESULTS: We included 34 233 patients with HFpEF from 224 sites with measured troponin levels (33.4% men; median age, 79 years): 78.6% (n = 26 896) with troponin I and 21.4% (n = 7319) with troponin T measurements. Among these, 22.6% (n = 7732) had elevation in troponin levels. In adjusted analysis, higher serum creatinine level, black race, older age, and ischemic heart disease were associated with troponin elevation. Elevated troponin was associated with higher odds of in-hospital mortality (odds ratio [OR], 2.19; 95% CI, 1.88-2.56), greater length of stay (length of stay >4 days OR, 1.38; 95% CI, 1.29-1.47), and lower likelihood of discharge to home (OR, 0.65; 95% CI, 0.61-0.71) independent of other clinical predictors and measured confounders. Presence of elevated troponin I levels was also significantly associated with increased risk of 30-day mortality (hazard ratio [HR], 1.59; 95% CI, 1.42-1.80), 30-day all-cause readmission (HR, 1.12; 95% CI, 1.01-1.25), and 1-year mortality HR, 1.35; 95% CI, 1.26-1.45). CONCLUSIONS AND RELEVANCE: Troponin elevation among patients with acutely decompensated HFpEF is associated with worse in-hospital and postdischarge outcomes, independent of other predictive variables. Future studies are needed to determine if measurement of troponin levels among patients with decompensated HFpEF may be useful for risk stratification.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Pandey A, Golwala H, Sheng S, et al. Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program. JAMA Cardiol. 2017. PMID: 28030747. doi:10.1001/jamacardio.2016.4726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。